GSK1940029 is primarily utilized in research settings as a potent and selective inhibitor of the enzyme phosphodiesterase 10A (PDE10A). This enzyme plays a significant role in the regulation of intracellular signaling pathways, particularly in the brain. By inhibiting PDE10A, GSK1940029 helps researchers study the enzyme's function and its impact on neurological disorders such as schizophrenia, Huntington's disease, and Parkinson's disease. It serves as a valuable tool in preclinical studies to explore potential therapeutic strategies targeting PDE10A, aiding in the development of novel treatments for these conditions. Additionally, its selective action allows for a better understanding of the specific biochemical pathways involved in these diseases, contributing to advancements in neuroscience and drug discovery.